refractory interstitial cystitis
Conditions
Interventions
The experimental group:Perform submucosal injection of 10 mL PRP (extracted from 50 mL of the patient's own whole blood) into the bladder, with a 2-week interval between the first and second injection
The control group:Receive a single injection of botulinum toxin into the bladder (dose 100u), with only one injection and no repeated injections
Sponsors
Gongli Hospital, Shanghai
Eligibility
Sex/Gender
All
Age
45 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age range of 45-65 years old, male or female not limited; 2. Patients who meet all diagnostic criteria for NIDDK interstitial cystitis (except for condition 2) are classified as non Hunner's type; 3. Willing to participate in this study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Serious underlying diseases, including: (1) Hypertension with systolic blood pressure >= 160mmHg or systolic blood pressure >= 110mmHg; (2) diabetes (fasting blood glucose >= 10 mmol/L) or poor blood glucose control; (3) Respiratory system disorders, with normal oxygen saturation below 95% or moderate to severe ventilation/diffusion dysfunction; (4) T lymphocyte tumors that cause systemic immune diseases; (5) Currently using anticoagulants or antiplatelet drugs; (6) Other serious illnesses that result in insufficient physical strength to climb three floors on their own. 2. Diseases of the urinary system, including: (1) Bladder or ureteral stones; (2) Recent (within 3 months) urinary tract infections; (3) Other pathological changes in the bladder, such as benign or malignant tumors of the bladder, urethral diverticulum, etc. 3. Other treatment influencing factors: (1) Platelet count<100 × 10^9/L, hemoglobin<100g/L; (2) History of allergies to bladder injection therapy; (3) Received bladder botulinum toxin injection treatment within the past 6 months. 4. Pregnant or lactating women 5. Patients with mental illness, cognitive impairment, or inability to understand and comply with research requirements. 6. There are other diseases that cannot accept platelet apheresis. 7. It is expected that data collection will not be completed during the follow-up period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ICSI(Interstitial Cystitis Symptom Index Score); | — |
Secondary
| Measure | Time frame |
|---|---|
| ICPI(Interstitial Cystitis Problem Index Score);PUF(Pelvic Pain and Urgency/Frequency Symptom Scale);VAS(Visual Analogue Scale for Pain);GRA(Interstitial Cystitis Problem Index Score);Average number of urinations per 24 hours;Functional bladder capacity(FBC);SAS(Self-Rating Anxiety Scale); | — |
Countries
China
Contacts
Public ContactLv Jianwei
Gongli Hospital, Shanghai
Outcome results
None listed